Vivitra 375 mg Trastuzumab injection

VIVITRA 375 MG is a high-potency targeted biological therapy containing Trastuzumab, a monoclonal antibody used to treat specific types of aggressive cancers. Manufactured by Zydus Lifesciences (Cadila), it is a high-quality biosimilar to the global brand Herceptin. Vivitra works by specifically targeting the HER2 (Human Epidermal Growth Factor Receptor 2) protein, which is overexpressed in certain cancer cells. By binding to these receptors, it inhibits the signals that tell cancer cells to grow and divide, while also signaling the immune system to destroy them. It is a cornerstone treatment for HER2-positive breast cancer and metastatic gastric (stomach) cancer.